vehicle

drug

Cassava Sciences Inc

action

The day to day price action of this limp dick is more painful to watch than slugs breeding.

$SAVA , this daily one way action is depressing.

Zero confidence in management based on both recent actions and historical issues with the FDA. 2.

$SAVA We may get frustrated with volatility, manipulation, and irregular daily price action

price

This is sickening that these crooks can manipulate the price like this. !!!

He invites shorts to destroy stock price.. pathetic!

Some had to drop in price a little first!

new employee mr. cook must be pissed as this is lower price than the shares he got it for.

All.u did was dilute the pps 
..and release to prs to kill the stock price and momentum  
 You did so well..you fxuking scumbag.

I hate the stock price runup leading to an announcement.

data

- 
$AVXL in comparison, boring as hell - whenever Missling talks people fall asleep and holding back data and further readouts without any logical explanation are red flags -

$SAVA 
Pyggie here was bullish a few days ago, folded like a pussy because he can’t read data, and now spews FUD, like a spoiled child, because he’s worried he may have paper-handed a monster.

but offer only the “opinion” that there was “possible data manipulation.”

$SAVA longtime biotech investor and my honest experience when a CEO promises good data and there is a long waiting period = not good.

Sentiment matters in this game, and unfortunately, this company has been drug through the mud for so long that good data might just get overlooked.

$SAVA The ironic and sad thing is that this ticker has been abused and manipulated so badly that even if it triples on upcoming data release it still won&#39;t come close to ATH achieved on much less evidence of safety and efficacy.

The CEO belongs in jail with all this pump and dump stock manipulation and data manipulation

just annoying we all get so worked up and insulting when we, the retail investor, can neither move Remi to release data early or in truth, move the SP by buying or selling a few hundred shares.

$SAVA dumb management causing longs to lose confidence, you dont change the date of data release every few weeks, just give a date when you are certain and stick with that, its that simple

BIIB with a 27% chance of no decline - so bad, how can they even publish data like that.

patient

however, if you are a family member of Alz patient think about how fatiguing emotionally and financially it is to change diapers, have your name forgotten, or even have to take a license away from an otherwise healthy person.

but your day will come when you will pay back way more than the damage you have caused and the lives you have threatened from being treated for a debilitating disease.

$ALZN $ATHA $ORMP $SAVA $SPRC yes then go back to your scam board clown no need to trap others in this scam .. we know what value SAVA brings to their AD patients

Lecanemab approved - IV  infusion..increased infection risk, inconvenient for patients with MD&#39;s fully aware 
of side effects: brain swelling and bleeding. 2.

Eventually, the  
AD patient is unable to perform daily functions.

But the monoclonal antibody treatment also carries risks of brain swelling and bleeding.

$BIIB - lied and tried to push their bad drug Aduhelm on unsuspecting patients (one of which is a family member of mine).

3 deaths in 1900 trial patients.. how many deaths is our FDA going to inflict on millions of folks who are supposed to take this death drugs that also happen to have near-zero efficacy?? SMH

Avxl, not good they didn&#39;t have an agreement in place “plan for approval“ before they started the test fase 2b 500 patients.

$SAVA It&#39;s not only CRUEL for anyone to be prescribing any of these MABs for AD patients, it&#39;s impractical for both patients and the healthcare system in general.

application

$SAVA Words  to  to  ignorant,  never  hype  a  employee  from  fda,  shady  shiat! 🤡🤡🤡😂😂😂

It doesn&#39;t matter if drugs for terminal illnesses, have been approved after 6 months, because there is endless manipulation here, and this waiting game is based on either FDA approval or denial based on corruption at the agency?

This is such crap with the FDA my Father died a year ago from it

$BIIB $SAVA You would need uncommon patience to not be crazy mad at the system for this shenanigan approval process and decision from the FDA.

Idiots with no respect for integrity continues  to run 
wild within the FDA.

$SAVA once again we got fu*ked by the evil BIIB + FDA.

$SAVA THIS is how corrupt our FDA and state medical boards are.

$BIIB $SAVA  
I tell ya why - FDA is corrupt deep in its root, period!

$SAVA nice volume pickup going into the close.

That’s a lot of money to invest multiple times on a promising treatment 🚀

This is the ONLY drug in HISTORY to improve cognition after 12 months.

$SAVA A safe drug that impacts both neurodegeneration and neuroinflammation is going to have potential treating other CNS diseases.

Proper stock and proper drug doesn&#39;t smell like a scam.

Deeply appreciative of the treatment that SAVA is working to deliver,

$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete

I’m holding long term because I truly believe this is the first effective Alz treatment to date.

business-result

But the company actually has never seen before wonderful results.

And, make no mistake, the result are impressive.

It is the best results that have been seen in AD.

This could be huge in eliminating artificial FUD against the top-line results.

$SAVA Market is moving higher as SAVA is expecting data results.

Anavex is late like the sun comes up and still produces great results.

MOST IMPORTANTLY, THE RESULTS MUST HAVE BEEN GOOD AND PROMISING at each snapshot that leads Remi to use the word &quot;Thrilled&quot; in Dec 6 PR.

Data tells me no safety issues, with a possible large therapeutic window.

Then they dropped the “good” totally “not disappointing” data that Remi was so “Thrilled” about.

This will go beyond parabolic on good data … literally no shares out there unless they offer new ones … $MDGL $VKTX $SLS $SAVA

SAVA data gets analyzed by multiple different labs and shows its cognition improvement in mild AD cases, safe and well-tolerated

$SAVA I love not being able to hold $28 off data that will keep it pinned here until 2024.

but the data to date would predict continued efficacy that will be nigh on impossible to ignore.

$SAVA Institutional buying says data is good!! !

I’ll keep buying until data comes out…

Excited for the next data unveiling….bring it on!

$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

This will bring in billions of revenue and it will make the life quality longer for AD patients.

This sub-set of patients improved -4.96 mean points on ADAS-Cog from baseline to month 12.

CURING LEUKEMIA isn&#39;t a fly by night thing with Gamma T Cells and they already have ONE COMPLETE RESPONSE curing someone in Stage 4 nonresponsive to other treatments!

The high number of the patients that went into CMS (which is 80% complete) is reassuring.

but reverses cognitive decline and improves quality of life for the patient AND the FAMILY!

but mostly new hope for all the families and patients with AZ.

Testing still continues, so in my way of thinking the real-world results in patients must be nothing short of excellent.

Hepion Pharmaceuticals Inc

hand

10% of the float is in institutional index funds hands and that is shite.

In the last 2 years many weak hands have lost money selling for desperation..We are all  Screwed since we were part of a well organized fraudulent plan.

Won’t give them another dollar from my hand earned money…

Where you  perhaps you planned to spend what time you have might , if you are caught , just slip out of your hands !

short

The naked shorters are starting to feel the cactus being slowly shoved up their asses.

$HEPA $CVNA Shorts in big trouble in both these tickers

$HEPA shorties better cover!! 🤦🏼‍♂️🤦🏼‍♂️🤡🤡😂😂😂

$HEPA it seems like shorts got caught naked.

Sit there bitching and complaining about shorts.

Shorts are trapped and face more issues as share prices continues rising.

shit

$HEPA Can someone please explain to me why longs keep torturing themselves day after day by holding on to this crap?

$HEPA MMs using six decimals is effing bullshit!

These investment vehicle are the &quot;crack&quot; of the stock market - very addictive.

I picked Hepion because I think it has the potential to be best in class for NASH and I like it&#39;s safety profile and delivery mechanism.

The only thing im sure about with this company is that its drug has great potential

This makes Rencofilstat a promising candidate for the treatment of a variety of diseases, including thromboembolic disorders, sepsis, and cancer.

if this is truly a 4B, 5B or more mkt cap drug it’ll ultimately end up with a SP in the hundreds of dollars (assuming RS goes through) and everyone will be happy in the long run.

Despite everything, the fact remains that absolutely nobody has come up with anything substantially bad to report about this amazing drug.

For any investor, being able to buy the company below cash value while getting the wonder drug, Rencofilstat, for free is a VERY attractive investment proposition.

That drug has been proven to be safe to be used in tandem with any other known drugs.

$HEPA this drug is game changer in hepatology!

2023 is going to be highlighted with a continuous cascade of amazingly positive PR’s confirming the fact (already documented in 300+ early clinical studies), that Rencofilstat is truly a Wonder Drug to be celebrated, with an extraordinarily large TAM.

news

$HEPA the consolidation over last weeks is bullish … one day it will explode above 0,88$ or maybe with Gap Up after news … the day is near , Szenario destroyed &lt; 0,66$

The news for $NVS and $PLRX closing their relationship in NASh is good for $HEPA, in my opinion.

prepare for the positive news they know is coming.

The good news is that this stock can be manipulated both ways.

$HEPA 20 something percent haircut over a great news.

$HEPA @BioTuesdays good to see bioTuesday has so much great HEPA news to put out that they have to release some of it on Wednesday ! 🤣

My recommendation is to trust the science and say Buy! Buy!

$HEPA Big nice buy orders being executed. @.

$HEPA this is an extreme buy and HOLD- no one should be selling a share

$HEPA Hold enjoy the ride 3+ million volume, there is something BIG going on..with the Implied VOlatality fluctuation and premium on options.

$HEPA Great pop in pre-market, has some good strength coming back after a big sell.

but that’s good for bios lately so after a morning dip $LABU goes higher taking us with it🤷 
go big blue!

Its definitely leaning towards a big run coming soon.

The volume today is going to activate alarm bells up &amp; down Wall Street and attract a lot of big money looking for a solid biotech investment. 🎉

$HEPA next leg up coming imo.. big news for a multi day run 🗞️

BIG props to our team of scientists, clinicians and entire team!! !

I can&#39;t stress enough how big a deal this is.

$HEPA deff see us making big $$$ at some point

Xeris Biopharma Holdings Inc

manipulation

$XERS  This stock has become totally distorted by Wall Street manipulators!

In fact its just market manipulation by  shorts and rich assholes who use stocks like slot machines.

$XERS This stock is heavily MANIPULATED by a &quot;Gang of Shortsellers&quot; and has nothing to do with a fair market price!

It is so obvious this is being systematically walked down (manipulated) and has nothing to do with the Company itself, products, or the overall market.

Just goes to show how badly manipulated this is.

The manipulation of these criminals is unbelievable.

This Share Price is still 
 
Crazy  
 
Stupid  
 
Low. Cheers!

$XERS  This share price is crazy stupid low.

You’d think Paul would have some shame being below their price.

What is most disappointing about XERS, except for the collapse in stock price, is the failure of management to do much of anything to encourage retail or institutional investors to continue to have the confidence in management of the company or its future.

I think price targets are fake… there compensated to make targets IMO.

suck

Unfortunately, the mkt sucks now and that’s reflected in sp.

The whole market sucks and this has been unjustly hammered.

$XERS this is so fucked up its unbelievable.

Invested a lot of money , and realizing we are fucked.

market

What a crappy market! Hopefully next week will be better:)

$XERS A bad market must admit it is really a bad day.

$XERS A 10+ cent drop when you only have 14 of those until 0 ahead of all that gobbledygook fundamental longs are spouting is not a great sign of market confidence.

$XERS market on a year and this lame duck is flat or sinking

but unfortunately, in this market, not cheap either, and even less an outright buy without a very very strong conviction.

Market hinting something is terribly wrong with this company.

revenue

$XERS High risk is an understatement with XERS, weak drug lineup, weak pipeline, revenue grow slowing, cash burn increasing and worse than weak management should tell you to stay away.

Nothing positive, revenue continues to slow, spending increasing, generics coming, recorlev under performing and most important, incompetent management! !

Personally, I think this is very conservative, and comes in below the Strongbridge &quot;Low Case&quot; from page 87 of the merger prospectus because it comes out to $172M annual revenue in 2023 compared to $216M revenue on the prospectus.

Revenues are slowing, expenses are increasing, tech is marginal, patents will be expiring, pipeline is horrible and management is horrible.

but also very disappointing that my EV charger stocks have $Billion mkt caps with less than $50M revenue and years from cash flow positive and yet.

Not only are the current drugs low revenue producers and the pipeline is horrible.

.WS not impressed with 3 low revenue drugs and weak pipeline.

Two other drugs, each growing revenue steadily.

A levothyroxine formulation that looks positive (most commonly prescribed drug) A full proven technology platform to deliver hard to administer drugs by a simple injection.

Two (2) other drugs, each growing revenue steadily.

We have other amazing drugs, Recorlev, Gvoke and more including some drugs yet to be approved.

That said, I fully expect continuing  script and revenue growth, upcoming cashflow breakeven and some nice juicy licensing deals to resolve that in the months ahead.

There is so much good news here, growing revenue, a stable base, conservative management, and connections to big pharma.

product

$XERS their primary product increases 9% week to week sales with an overall trend that&#39;s incredible.

$XERS I like their products and the inject opportunity with Horizon Tepezza is huge I wish they weren&#39;t acquired so they can keep a focus on that.

Earnings are growing and there could be great news any day from a variety of sources, whether a collab exercise of option, new product collab, royalty pmt, etc.

More important is that they grow Recorlev&#39;s revenue at high(er) speed, and continue to gain market share with Gvoke without product price drop.

Revenue exploding on the upside with
their 4 products.

Even if they have more short term gains coming soon, we know the Gvoke product will gain share back due to the more pleasant experience. Patience.

Gvoke is the best and easiest product out there.

Products have been approved and much more is coming, wait and relax.

For a tiny company like xeris to go toe to toe with lilly and grow share shows they have the best product.

$XERS Truly so strange, everything Xeris had in its programme has been met, briefly 3 FDA approved products, collaborations with major pharmacies and much, much more.

$XERS Good market yesterday, looking good today and good old XERS continues in the tank!!

but all of last week, in the middle of heavy market turmoil where we normally go down heavily, we stayed up and rose. Why?

Plenty of small caps were brought to lows (and thus made good buys) before starting recovery in this bear market, $ADMA, $ARAY, $PRTK, $CDTX, they all have turned or are turning around cause there is deep value and a clear path to profitability.

Top Stocks matching your search for "delivery treatment"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Mar, 17, 2023

Mar, 10, 2023

HEPA

Hepion Pharmaceuticals Inc

-16.85%

$0.86 - $0.72

Mar, 17, 2023

Dec, 21, 2022

XERS

Xeris Biopharma Holdings Inc

15.52%

$1.16 - $1.34

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Mar, 17, 2023

Mar, 10, 2023

Oct, 29, 2022

HEPA

Hepion Pharmaceuticals Inc

-16.85%

$0.86 - $0.72

Mar, 17, 2023

Dec, 21, 2022

XERS

Xeris Biopharma Holdings Inc

15.52%

$1.16 - $1.34